Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 39.4 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; titanium dioxide; purified talc; sodium stearylfumarate; purified water; iron oxide yellow; croscarmellose sodium; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oseltamivir str is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir str is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 98.5 mg - capsule, hard - excipient ingredients: purified talc; gelatin; purified water; croscarmellose sodium; povidone; iron oxide red; sodium stearylfumarate; titanium dioxide; iron oxide yellow; pregelatinised maize starch; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oseltamivir str is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir str is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 39.4 mg - capsule, hard - excipient ingredients: gelatin; purified water; povidone; titanium dioxide; croscarmellose sodium; pregelatinised maize starch; purified talc; sodium stearylfumarate; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - osmivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,osmivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 59.1 mg - capsule, hard - excipient ingredients: purified water; gelatin; iron oxide black; sodium stearylfumarate; croscarmellose sodium; pregelatinised maize starch; titanium dioxide; purified talc; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - oseltamivir str is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir str is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 59.1 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; titanium dioxide; purified talc; iron oxide black; croscarmellose sodium; povidone; sodium stearylfumarate; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - osmivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,osmivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 98.5 mg - capsule, hard - excipient ingredients: titanium dioxide; purified water; gelatin; pregelatinised maize starch; iron oxide yellow; sodium stearylfumarate; povidone; iron oxide red; purified talc; croscarmellose sodium; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - osmivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,osmivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.4 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose; macrogol 6000; sodium starch glycollate; mannitol; calcium stearate; sodium carbonate; crospovidone; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) duodenal ulcer; ii) gastric ulcer; iii) gastro-oesophageal reflux disease (gord): symptomatic gord. the treatment of heartburn and other symptoms associated with gord; reflux oesophagitis; iv) gastrointestinal lesions refractory h2 blockers; v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.7 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: sodium starch glycollate; hypromellose; sodium carbonate; crospovidone; colloidal anhydrous silica; mannitol; sodium hydroxide; calcium stearate; macrogol 6000; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) duodenal ulcer; ii) gastric ulcer; iii) gastro-oesophageal reflux disease (gord): symptomatic gord. the treatment of heartburn and other symptoms associated with gord; reflux oesophagitis; iv) gastrointestinal lesions refractory h2 blockers; v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - mirtazapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; colloidal anhydrous silica; maize starch; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow - treatment of major depression including relapse prevention.